MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

PartnershipInhaled Rapid-Acting, Short-Duration GLP-1Positive

AI Analysis

Summary

MannKind entered a licensing and collaboration agreement with Rose Pharma Inc to develop an inhaled rapid-acting, short-duration GLP-1 therapeutic for weight management. The partnership expands MannKind's GLP-1 portfolio through an inhaled delivery approach.

Importance:7/10

Sentiment:

0.60

licensingcollaborationGLP-1weight managementinhaled

Related Companies

$MNKD

Read the original article

Published by yahoo_finance on September 9, 2026 10:30 AM

Read Original